Among the pharmacogenetic factors influencing toxicity of commonly used B-ALL treatments, variants in the <i>TPMT</i> and <i>NUDT15</i> genes, both involved in the metabolism of 6-mercaptopurine, represent the most robust and clinically validated predictors. The gene discussed is TPMT; the disease is precursor B-cell acute lymphoblastic leukemia.